US Patent Competitiveness Erosion – Judicially-Created Obviousness-Type Double Patenting Doctrine

This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →

## US Patent Competitiveness Erosion – Judicially-Created Obviousness-Type Double Patenting Doctrine ### Overview IPWatchdog reporting (June 14, 2026) argues that the United States is uniquely disadvantaged globally due to judicially-created patent doctrine — specifically, obviousness-type double patenting (ODP) — which forces patent term truncation on related patent families in a manner no other major jurisdiction replicates. This is a developing narrative in the context of the broader U.S. patent competitiveness debate tracked in existing wiki pages on PTAB institution rate decline and patent enforcement asymmetry. ### Core Legal Issue According to IPWatchdog (June 14, 2026): - The U.S. is the **only country** where the judiciary imposes patent term truncation across unrelated patent families via ODP doctrine - **Europe, China, and most other nations** apply a "novelty only" standard for applications filed before publication of an earlier-filed patent, and a "novelty and inventive step" standard for applications filed after publication — a framework IPWatchdog characterizes as working "well" (IPWatchdog, June 14, 2026) - U.S. ODP doctrine is judge-made, not statutory, which limits legislative remedies and concentrates the fix in either judicial reversal or congressional action ### Relationship to Existing Tracked Issues This narrative intersects with: - **Ex Parte Baurin (PTAB)**: PTAB is actively reconsidering ODP standards in the post-grant context (existing wiki page) - **IPR Institution Rate Decline**: Broader patent holder disadvantage in U.S. post-grant proceedings - **Patent Enforcement Asymmetry**: U.S. patent holders face structural disadvantages relative to foreign competitors whose home jurisdictions provide stronger patent protection ### Strategic Implications - **Pharma & biotech**: ODP doctrine most acutely affects pharmaceutical patent families, where continuation strategies are essential; truncated terms can eliminate years of exclusivity - **Patent prosecution attorneys**: Portfolio strategy must account for U.S.-specific terminal disclaimer requirements and the risk of invalidating related patents through ODP challenges - **IP policy advocates**: The judicially-created nature of the doctrine is both the problem and the potential solution — a Federal Circuit en banc ruling or SCOTUS review could resolve it without legislation - **Multinational filers**: Companies filing in both the U.S. and Europe/China face asymmetric protection terms that may affect where R&D investment is directed ### Open Questions - Whether the Federal Circuit will take up ODP doctrine reform en banc following Ex Parte Baurin - Whether Congress will act to codify a statutory double-patenting standard aligned with international norms - How ODP interacts with patent term adjustment (PTA) and patent term extension (PTE) in pharmaceutical contexts